Vivus - Company & Market Research Reports

VIVUS is a biopharmaceutical company that develops and commercializes therapies to address unmet medical needs in the United States and the European Union. The company’s lead product Qsymia is a combination appetite suppressant/stimulant and seizure medication indicated as an adjunct to a reduced-calorie diet and increased physical activity for chronic weight management in overweight and obese adults. VIVUS was founded in 1991 and is headquartered in Campbell, California.

From
From
From
From
From
From
From
Obesity - Pipeline Review, H1 2018 - Product Thumbnail Image

Obesity - Pipeline Review, H1 2018

  • Drug Pipelines
  • 526 Pages
From
Obesity - Pipeline Review, H2 2017 - Product Thumbnail Image

Obesity - Pipeline Review, H2 2017

  • Drug Pipelines
  • 518 Pages
From
PDE Inhibitors Market, 2016-2026 - Product Thumbnail Image

PDE Inhibitors Market, 2016-2026

  • Report
  • 223 Pages
From
From
Type 2 Diabetes - Pipeline Review, H1 2018 - Product Thumbnail Image

Type 2 Diabetes - Pipeline Review, H1 2018

  • Drug Pipelines
  • 1109 Pages
From
Type 2 Diabetes - Pipeline Review, H2 2017 - Product Thumbnail Image

Type 2 Diabetes - Pipeline Review, H2 2017

  • Drug Pipelines
  • 1126 Pages
From
From
From
From
From
From
Loading Indicator
adroll